Discovery of 2,4-diamino-5-cyanopyrimidine derivatives as protein kinase C theta inhibitors with mitigated time-dependent drug-drug interactions

Add time:08/06/2019    Source:sciencedirect.com

Protein kinase C theta (PKCθ) plays a critical role in T cell signaling and has therapeutic potential for T cell-mediated diseases such as transplant rejection and rheumatoid arthritis. PKCθ inhibitors have emerged as effective immunomodulative agents for the prevention of transplant rejection. We previously reported that the 2,4-diamino-5-cyanopyrimidine derivative 2 was a potent PKCθ inhibitor; however, it exhibited CYP3A4 time-dependent inhibition (TDI). Here, we report the structural modification of compound 2 into 34 focusing on mitigating CYP3A4 TDI. Compound 34 exhibited potent in vitro activity with mitigated CYP3A4 TDI and efficacy in vivo transplant model.

We also recommend Trading Suppliers and Manufacturers of 4-AMINO-2-ETHYLSULFANYL-PYRIMIDINE-5-CARBONITRILE (cas 16462-29-6). Pls Click Website Link as below: cas 16462-29-6 suppliers

Prev:Azoles. Part 43:1 Reactions of N-(Phenylsulphonylmethyl)- and N-(Phenylsulphinylmethyl)azoles with some Nitroarenes
Next:Facile synthesis and biological activities of novel fluorine-containing pyrido[4,3-d]pyrimidines)